Why the study?
It is unknown whether tailoring DOAC therapy to achieve optimal drug levels improves clinical outcomes, and data regarding the clinical efficacy and safety of tailored DOAC regimens are lacking.
Does tailored direct oral anticoagulation improve clinical outcomes in patients with atrial fibrillation?
Population
Patients with AF
Design
Review
Authors
Loading...
Tailored DOAC regimens lack outcome data in AF; leaves open whether laboratory-guided dosing improves safety or efficacy.
Does tailored direct oral anticoagulation improve clinical outcomes in patients with atrial fibrillation?
This review highlights the current lack of data on the clinical efficacy and safety of tailoring DOAC therapy based on drug levels in patients with atrial fibrillation.
Samoš et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: